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molecular chaperone activity (clusterin). Interestingly, other proteomic
studies have identiﬁed clusterin and CILP-1 as being upregulated in early
human OA. These biomarkers may be involved in early repair responses
in cartilage and thus may be useful for the detection of early changes in
OA.
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A41 EPHB4 RECEPTOR ACTIVATION BY ITS SPECIFIC LIGAND
EPHRIN B2 INDUCED A REDUCED REMODELING PROCESS
IN HUMAN SUBCHONDRAL BONE OSTEOBLASTS
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Purpose: Ephrin is well documented in the literature for its functions in
the nervous and cardiovascular systems. However, it has recently been
shown that the interaction of the EphB4 receptor with its speciﬁc ligand
ephrin B2 could be implicated in the physiological regulation of bone
homeostasis. Osteoarthritis (OA), although characterized by cartilage
breakdown and inﬂammation of the synovial membrane, also demon-
strates important changes in the subchondral bone. Recent studies have
shown that an abnormal remodeling process of this tissue is intimately
involved in the genesis of OA. We recently classiﬁed human OA sub-
chondral bone osteoblasts into two subgroups according to their low (L)
or high (H) PGE2 levels. Further data demonstrated that the L-OA showed
bone pro-resorption activities and the H-OA pro-formation properties. In
this study we determined the presence, level and modulation of EphB4
receptors on each of these subgroups. Further, we investigated the
modulation of EphB4 receptors and the effect of their activation by ephrin
B2 on OA osteoblasts.
Methods: The in situ presence of EphB4 receptors in the subchondral
bone was determined by immunohistochemistry. The EphB4 receptor
expression level, modulation upon treatment with osteotropic factors,
and effect of activation by ephrin B2 on bone catabolic mediators were
determined using real-time PCR. The ephrin B2-activated EphB4 receptor
effect on the bone resorption activity was also determined using a co-
culture system of differentiated human PBMC and human subchondral
bone osteoblasts. The intra-cellular signaling pathways employed by the
EphB4 receptor activation were investigated by speciﬁc ELISA.
Results: Data showed that EphB4 receptors were present in the human
subchondral bone osteoblasts and osteocytes. A signiﬁcant increase in
EphB4 receptor expression level was found in the L-OA osteoblasts
compared to the normal (p< 0.002) and the H-OA (p< 0.0007). However,
there was no difference between the normal and the H-OA. EphB4
receptor levels in the L-OA osteoblasts were signiﬁcantly up-regulated
by PGE2 and Il-17. Interestingly, ephrin B2, PGE2 and Il-17 signiﬁcantly
inhibited the bone resorption activity in L-OA osteoblasts. EphB4 ac-
tivation by ephrin B2 signiﬁcantly inhibited the expression level of the
pro-inﬂammatory cytokines Il-1b and Il-6, the metalloproteases MMP-1,
MMP-9 and MMP-13, as well as RANKL. The factors MMP-2 and OPG
were not modulated. The EphB4 receptor activation signiﬁcantly reduced
the PI3K/Akt pathway, but had no signiﬁcant effect on the MAP kinases.
Conclusions: This study, for the ﬁrst time, provides evidence that EphB4
receptor activation by ephrin B2 in human OA subchondral bone could
impact abnormal metabolism in this tissue by inhibiting resorption factors
and their activities. The differential level of EphB4 receptors in the L-OA
and H-OA subchondral bone osteoblasts also indicates that these cells
have reached a different pathological stage. Data from this study bring to
light that ephrin B2 could be targeted as a speciﬁc therapeutic approach
in the development of a disease modifying OA drug, as this factor could
exert a protective effect on OA articular tissue structural changes.
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Purpose: Although a signiﬁcant genetic effect on hand osteoarthritis (OA)
has been reported, conﬁrmed replicated genetic factors have not yet been
identiﬁed. The aim of this study, therefore, was to identify speciﬁc genetic
polymorphisms for hand OA by means of the genome-wide association
study (GWAS) in Caucasian population.
Methods: A three stage approach was utilized. First, we conducted
a GWAS implementing 317,818 SNPs across the entire genome in
651 women of the North European origin from the TwinsUK registry. Next,
we tested the top 100 SNPs identiﬁed in our GWAS in the Rotterdam
cohort, consisting of 1438 men and women aged over 50. In the ﬁnal
stage, we searched for conﬁrmation of the association between the OA
and SNPs that showed the most signiﬁcant association results in the
second stage. To this aim we used additional independent population-
based sample – the Chingford Study, including 671 British women. All
participants in the study had their both hands X-rayed, and 15 joints on
each hand (DIP, PIP, MCP, and ﬁrst CMC) were scored for OA, using
Kellgren-Lawrence (KL) system. The total KL score adjusted for age (and
sex) was used in the analysis.
Results: We identiﬁed replicated evidence of an association between
the SNP which is located in chromosome16p13 and hand OA. The minor
allele with a frequency of 32% signiﬁcantly decreased (b=−0.16±0.03
SE) the total KL score of the hands (combined p=8.46×10−7) in all three
cohorts combined. When we categorized the participants of the TwinsUK
and the Chingford study into two groups: people who had at least two
joints of hands affected, deﬁned by KL 2, vs individuals who didn’t have
any hand’s joints affected, the minor allele was associated with a 33%
reduction of risk in the development of hand OA (p = 0.0002). The risk
was further reduced to 41% if the cases are deﬁned as at least three
joints affected (p = 0.00001).
Conclusions: This genome-wide scan identiﬁed a signiﬁcant association
between OA and a novel locus which has a potential role in transcriptional
regulation of calcitonin. This ﬁnding provides insight into previously un-
known genetic mechanisms in the development of hand OA.
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AREA TO KNEE PAIN SEVERITY AND INCIDENT FREQUENT
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Purpose: Subchondral bone has attracted attention as a potential source
of pain in knee OA in part because of its intimate relationship to overlying
cartilage and its load bearing function. With full thickness cartilage
defects, exposed bone may be more likely to generate joint pain during
contact and weightbearing activity. We hypothesized that (1) increased
%denuded bone in OA knees is associated with increased pain and
(2) greater %denuded bone predicts incident frequent knee pain.
Methods: All participants had knee OA by deﬁnite osteophytes. Axial
and double oblique coronal SPGRwe sequences were acquired on a
1.5T or a 3T scanner. Images were processed with proprietary software
(Chondrometrics). Manual segmentation by trained readers was used
to compute total area of subchondral bone, cartilage surface area, and
cartilage-covered and denuded areas of bone for the medial tibia, lateral
tibia, weightbearing medial and lateral femur, and patella. Pain severity
was assessed with a knee-speciﬁc 100mm VAS for pain in the past
week. Frequent knee pain was deﬁned as pain in or around the knee
for most days in the past month. To test hypothesis 1, we used median
quantile regression to determine the increase in median pain score per
10% increase in denuded bone, analyzing the more painful knee. To test
hypothesis 2, we used logistic regression with GEE to estimate the odds
ratio (OR) per 10% increase in denuded bone at baseline for baseline-
to-2 year incident frequent knee pain. Analyses were adjusted for age,
gender, BMI, K/L grade, and bone edema score.
Results: 184 participants (age 66, BMI 30, 78% women) made up the
sample for hypothesis 1. As in Table 1, greater %denuded bone in the
noted medial surfaces was associated with increased median pain score.
176 knees in 119 persons (age 68, BMI 29, 74% women) did not have
frequent knee pain at baseline and made up the sample for hypothesis 2.
Of the 176 knees, 53 developed frequent knee pain over the next 2 years.
As in Table 2, greater %denuded bone at baseline was associated with
an increase in the adjusted odds for incident frequent knee pain.
Conclusions: Greater %denuded bone was associated with greater knee
pain severity. In knees without frequent pain at baseline, %denuded bone
predicted incident frequent knee pain. These results support that the
exposure of subchondral bone may be a source of pain in knee OA.
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Table 1. Hypothesis 1
% denuded bone, analyzed at: Increase* in median pain score,
per 10% increase in denuded
bone, adjusted for age, gender,
BMI, bone edema score (95%CI)
Medial tibial surface 4.46 (1.45, 7.47)
Weightbearing medial femoral surface 5.24 (3.19, 7.28)
Medial tibial + weightbearing medial femoral surface 6.35 (3.10, 9.59)
Medial tibial + weightbearing medial femoral + patellar 6.19 (1.28, 11.10)
*signiﬁcant if 95%CI excludes 0.
Table 2. Hypothesis 2
% denuded bone, analyzed at: Age, gender, BMI, K/L grade,
bone edema score-adjusted OR*
per 10% increase in denuded bone
(95%CI)
Medial tibial surface 1.61 (1.07, 2.42)
Weightbearing medial femoral surface 1.49 (1.13, 1.95)
Medial tibial + weightbearing femoral 1.61 (1.15, 2.26)
Medial tibial + weightbearing medial femoral + patellar 2.44 (1.50, 3.96)
*signiﬁcant if 95%CI excludes 1.
A44 THE EFFECT OF CHONDROITIN SULFATE ON
STRUCTURE MODIFICATION IN PATIENTS WITH KNEE
OSTEOARTHRITIS: A META-ANALYSIS OF RANDOMIZED
PLACEBO-CONTROLLED TRIALS
M.C. Hochberg, M. Zhan, P. Langenberg. University of Maryland,
Baltimore, MD, USA
Purpose: To determine the effect of chondroitin sulfate on structure
modiﬁcation, as measured by change in the rate of decline in minimum
joint space width, in patients with osteoarthritis (OA) of the knee.
Methods: The authors searched MEDLINE from 1996 to 2007 to identify
articles on the effect of chondroitin sulfate on structure modiﬁcation in
patients with knee OA. The reference lists of systematic reviews and
meta-analyses were searched and authors were contacted to identify
additional studies. The primary outcome was the change in minimal joint
space width over one year. One person abstracted data on the change in
minimum joint space width in the placebo-treated and chondroitin sulfate-
treated groups. Whenever possible, we used data from the intention-
to-treat analyses for pooling. For studies of two years in duration, we
assumed that the change was linear over time. Results were summarized
for both the absolute difference between the chondroitin sulfate and
placebo-treated groups as well as the standardized mean difference
(effect size) using the pooled standard deviations. Fixed effects models
were used as the Q and I2 statistics showed no evidence of between-trial
heterogeneity. Sensitivity analyses were also performed.
Meta-analysis of randomized controlled trials of chondroitin sulfate for structure modiﬁcation
Author Chondroitin Sulfate Placebo Difference (mm/year) Effect Size
(Year) No. of
patients
Mean
decline
SD No. of
patients
Mean
decline
SD Mean (95%CI) SMD (95%CI)
Uebelhart
(1998)
14 −0.1 1.24 12 0.4 1.00 −0.50 (−1.36, 0.36) −0.43
(−1.21, 0.36)
Uebelhart
(2004)
39 0.04 0.83 39 0.32 1.12 −0.28 (−0.72, 0.16) −0.28
(−0.73, 0.16)
Michel
(2006)
150 −0.02 0.24 150 0.04 0.28 −0.06 (−0.12, 0.00) −0.23
(−0.46, 0.00)
Reginster
(2007)
309 0.05 0.26 313 0.12 0.27 −0.07 (−0.11, −0.03) −0.26
(−0.42, −0.11)
Summary 512 514 −0.07 (−0.10, −0.03) −0.26
(−0.38, −0.l4)
Results: Six reports of 4 placebo-controlled trials of chondroitin sulfate
in patients with knee OA that reported changes in joint space width were
identiﬁed, including 5 articles (3 that reported on the same trial) and 1
conference abstract. Two trials each were of one and two years in dura-
tion. Overall, the 4 trials enrolled a total of 1026 patients (512 randomized
to chondroitin sulfate and 514 to placebo) (see Table). One pilot study,
including only 26 patients, was published in 1998; the remaining three
trials were published in 2004 or later.
The meta-analysis of all 4 trials found a mean difference of 0.07mm per
year (95% conﬁdence intervals [CI] 0.03, 0.10) in favor of chondroitin
sulfate for retarding the decline in minimal joint space width (P< 0.0001).
This corresponds to an effect size of 0.26 (95%CI: 0.14, 0.38). Sensitivity
analyses excluding the trial published only in abstract form (Reginster
et al [2007]) or excluding the two small trials of only one year in duration
(Uebelhart et al [1998 and 2004]) showed similar signiﬁcant results.
Conclusions: This meta-analysis demonstrates a signiﬁcant small-to-
moderate effect of chondroitin sulfate as a structure modifying drug
for treatment of patients with knee OA as measured by slowing the
rate of decline in minimum joint space width. These results support
recent OARSI treatment recommendations for use of chondroitin sulfate
in patients with knee OA.
A45 INDIRECT COMPARISON OF CLINICAL EFFICACY ACROSS
COCHRANE REVIEWED PHYSIOTHERAPY INTERVENTIONS
FOR PATIENTS WITH OSTEOARTHRITIS: A META-ANALYSIS
WITH MIXED TREATMENT COMPARISONS
H. Lund Sr1, R. Christensen2, H. Bliddal2. 1Institute of Sports Science
and Clinical Biomechanics, Odense, DENMARK, 2The Parker Institute,
Frederiksberg, DENMARK
Purpose: There have been numerous of systematic reviews of interven-
tions designed to diminish pain and improve function for patients with
OA, but the comparable effectiveness of such interventions is unclear.
To assess the clinical efﬁcacy of physiotherapeutic (PT) modalities and
interventions available in library of Cochrane reviews, on the pain and
disability in patients with osteoarthritis (OA), applying data from published
systematic Cochrane reviews of RCTs would be a useful method.
Methods: The Cochrane Library was searched for Cochrane reviews
considering patients with OA and different physiotherapeutic interventions
with the aim of reducing pain, and disability. A meta-regression analysis
was applied, for the mixed treatment comparisons, applying the individual
study’s standardized mean difference (SMD) as outcome measure, for
pain and disability, respectively. The statistical random-effects model
was based on a restricted maximum likelihood (REML), mixed-effects
model procedure with intervention as ﬁxed- and trial as random-factor,
respectively. The within study variance was considered known for each
published RCT, based on the explicit SD’s presented in each of the
original Cochrane reviews. A negative SMD favors the intervention on
trial.
Results: The search with “osteoarthritis” in the title resulted in 35 re-
views. Reasons for exclusion was protocols (K = 12), pharmacological
treatments and surgery (K=15), withdrawn (K=1) and 1 study compared
two different kinds of treatment (K = 1). Thus, 6 Systematic Cochrane
Reviews were included in the meta-regression model (patients included,
N=3,016): Lateral wedged insoles (LWI, pain k = 1; disability k = 1),
electromagnetic ﬁeld therapy (EMF, pain k = 2; disability k = 2), exercise
(EXE, pain k = 17; disability k = 18), ultrasonic therapy (UST, pain k = 1;
disability k = 0), thermotherapy (THT, pain k = 1; disability k = 1), and
transcutaneous electrical nerve stimulation (TENS, pain k = 6, disability
k = 1).
Based on the indirect meta-analysis we were able to rank these 6 mutually
independent interventions according to the published efﬁcacy on pain;
data are presented in descending efﬁcacy (SMD) order with the corre-
sponding p-value: EMF (SMD: −1.13, p = 0.003); THT[cold] (SMD: −0.69,
p = 0.21); TENS (SMD: −0.45, p = 0.003); EXE (SMD: −0.43, p = 0.0001);
LWI (SMD: 0.31, p = 0.45); UST (SMD: 0.43, p = 0.34). According to the
published efﬁcacy on disability: THT[cold] (SMD: −1.96, p< 0.0001); EMF
(SMD: −0.81, p = 0.002); TENS (SMD: −0.60, p = 0.08); EXE (SMD: −0.34,
p< 0.0001); LWI (SMD: 0.30, p = 0.24).
Conclusions: Based on this mixed treatment comparison, we provide
quantitative evidence-based efﬁcacy ranking of the PT interventions cur-
rently available as an updated Cochrane review. Based on the reported
pain and disability reduction, it is highly evident (p< 0.0001) that exercise
therapy does beneﬁt the patient; although not necessarily with the largest
magnitude of efﬁcacy. Of the other therapies tested, both EMF and
TENS showed a relevant effect size of moderate statistical signiﬁcance
(p = 0.003 respectively p = 0.03) on pain. In addition, THT and EMF
showed a clinically relevant effect size on disability reduction (p< 0.0001
respectively p = 0.002). The present indirect-comparison provide the clin-
ician a review of the modalities to choose, accordingly LWI, UST might
not be effective in the treatment of osteoarthritis.
A46 TAI CHI IS EFFECTIVE IN TREATING KNEE
OSTEOARTHRITIS: A RANDOMIZED CONTROLLED TRIAL
C. Wang, C. Schmid, P. Hibberd, R. Kalish, R. Roubenoff, R. Rones,
A. Okparavero, T. McAlindon. Tufts Medical Center, Boston, MA, USA
Purpose: Knee osteoarthritis (KOA) is a major cause of pain and
functional impairment among elders and has no medical remedy. The
